{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:19:38Z","timestamp":1794475178453,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1053\/j.gastro.2022.09.041","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:34:46Z","timestamp":1665401686000},"page":"61-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":168,"title":["Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial"],"prefix":"10.1053","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4296-7901","authenticated-orcid":false,"given":"Loren","family":"Laine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"DeVault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Mitev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Spechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.09.041_bib1","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis","volume":"10","author":"Nirwan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2022.09.041_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.gastro.2021.10.017","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021","volume":"162","author":"Peery","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.09.041_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/1998\/925346","article-title":"The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts","volume":"12","author":"Thomson","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00365520510011579","article-title":"High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report","volume":"40","author":"Ronkainen","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease","volume":"117","author":"Katz","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2022.09.041_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","article-title":"Appropriate acid suppression for the management of gastro-oesophageal reflux disease","volume":"51","author":"Bell","year":"1992","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2022.09.041_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.03235.x","article-title":"Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis","volume":"25","author":"Katz","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib8","series-title":"Takeda Pharmaceuticals America, Inc. Prevacid (lansoprazole) and Prevacid Solutab (lansoprazole). Prescribing information","year":"2020"},{"key":"10.1053\/j.gastro.2022.09.041_bib9","series-title":"AstraZeneca. Nexium (esomeprazole magnesium). Prescribing information","year":"2021"},{"key":"10.1053\/j.gastro.2022.09.041_bib10","series-title":"Pfizer. Protonix (pantoprazole sodium). Prescribing information","year":"2020"},{"key":"10.1053\/j.gastro.2022.09.041_bib11","series-title":"Eisai, Inc. Aciphex (rabeprazole sodium). Prescribing information","year":"2020"},{"key":"10.1053\/j.gastro.2022.09.041_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10620-005-9071-3","article-title":"A\u00a0multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis","volume":"51","author":"Lightdale","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.09.041_bib13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cgh.2006.03.006","article-title":"Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams","volume":"4","author":"Devault","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.09.041_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2022.09.041_bib15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","article-title":"Review article: potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Abdel-Aziz","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects","volume":"117","author":"Laine","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.09.041_bib20","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","article-title":"The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase","volume":"42","author":"Scott","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.09.041_bib22","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib23","first-page":"1749","article-title":"Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group","volume":"91","author":"Castell","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1572-0241.1998.00238.x","article-title":"A\u00a0placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis","volume":"93","author":"Earnest","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2036.2009.03954.x","article-title":"Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/gut.36.4.539","article-title":"Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole","volume":"36","author":"Verdu","year":"1995","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.09.041_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0016-5085(99)70544-5","article-title":"Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole","volume":"117","author":"Holtmann","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.09.041_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000446301","article-title":"Different pathophysiology of gastritis between east and west? An Asian perspective","volume":"1","author":"Suzuki","year":"2016","journal-title":"Inflamm Intest Dis"},{"key":"10.1053\/j.gastro.2022.09.041_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.7326\/0003-4819-124-10-199605150-00001","article-title":"Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Robinson","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2022.09.041_bib30","first-page":"1758","article-title":"Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy","volume":"91","author":"Sontag","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.09.041_bib31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib32","doi-asserted-by":"crossref","first-page":"zqab062","DOI":"10.1093\/function\/zqab062","article-title":"Gastrin: from physiology to gastrointestinal malignancies","volume":"3","author":"Duan","year":"2022","journal-title":"Function (Oxf)"},{"key":"10.1053\/j.gastro.2022.09.041_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/gast.2003.50091","article-title":"Gastrin induces proliferation in Barrett\u2019s metaplasia through activation of the CCK2 receptor","volume":"124","author":"Haigh","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.09.041_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(18)31388-6","article-title":"Esomeprazole and aspirin in Barrett\u2019s oesophagus (AspECT): a randomized factorial trial","volume":"392","author":"Jankowski","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2022.09.041_bib36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","article-title":"Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy","volume":"24","author":"Jalving","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.09.041_bib37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cgh.2009.05.015","article-title":"No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients","volume":"7","author":"Genta","year":"2009","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522011635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522011635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:37:38Z","timestamp":1758037058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522011635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0016508522011635"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.09.041","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}